Global CD30 (TNFRSF8) Antibody Market Research Report 2026(Status and Outlook)
CD30 (TNFRSF8) Antibody is an antibody specific for CD30 protein.CD30 is a member of the tumor necrosis factor receptor superfamily, mainly expressed on the surface of lymphocytes and some cancer cells. It plays a role in the regulation of cell growth, survival and differentiation, and its expression is increased in some malignant tumors such as lymphoma. The application of CD30 antibody can help to study the expression pattern and function of CD30 protein, especially in tumor research to help analyze its mechanism of action. In view of the important role of CD30 in cancer, CD30 antibody has potential application value in tumor therapy, diagnosis and research, and may provide useful information and tools for related fields.
The global CD30 (TNFRSF8) Antibody market size was estimated at USD 493.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global CD30 (TNFRSF8) Antibody market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global CD30 (TNFRSF8) Antibody market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the CD30 (TNFRSF8) Antibody market.
Global CD30 (TNFRSF8) Antibody Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Sino Biological, Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co., Ltd.
Boster Biological Technology
MyBiosource, Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology, Inc.
Creative Diagnostics
OriGene Technologies, Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Market Segmentation (by Type)
Monoclonal Antibody
Polyclonal Antibody
Market Segmentation (by Application)
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
Geographic Segmentation
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the CD30 (TNFRSF8) Antibody Market
Overview of the regional outlook of the CD30 (TNFRSF8) Antibody Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CD30 (TNFRSF8) Antibody Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of CD30 (TNFRSF8) Antibody, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global CD30 (TNFRSF8) Antibody market size was estimated at USD 493.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global CD30 (TNFRSF8) Antibody market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global CD30 (TNFRSF8) Antibody market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the CD30 (TNFRSF8) Antibody market.
Global CD30 (TNFRSF8) Antibody Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Sino Biological, Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co., Ltd.
Boster Biological Technology
MyBiosource, Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology, Inc.
Creative Diagnostics
OriGene Technologies, Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Market Segmentation (by Type)
Monoclonal Antibody
Polyclonal Antibody
Market Segmentation (by Application)
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the CD30 (TNFRSF8) Antibody Market
Overview of the regional outlook of the CD30 (TNFRSF8) Antibody Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CD30 (TNFRSF8) Antibody Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of CD30 (TNFRSF8) Antibody, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of CD30 (TNFRSF8) Antibody
1.2 Key Market Segments
1.2.1 CD30 (TNFRSF8) Antibody Segment by Type
1.2.2 CD30 (TNFRSF8) Antibody Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CD30 (TNFRSF8) ANTIBODY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CD30 (TNFRSF8) ANTIBODY MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global CD30 (TNFRSF8) Antibody Product Life Cycle
3.3 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2020-2025)
3.4 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2020-2025)
3.5 CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global CD30 (TNFRSF8) Antibody Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 CD30 (TNFRSF8) Antibody Market Competitive Situation and Trends
3.8.1 CD30 (TNFRSF8) Antibody Market Concentration Rate
3.8.2 Global 5 and 10 Largest CD30 (TNFRSF8) Antibody Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 CD30 (TNFRSF8) ANTIBODY INDUSTRY CHAIN ANALYSIS
4.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CD30 (TNFRSF8) ANTIBODY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global CD30 (TNFRSF8) Antibody Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to CD30 (TNFRSF8) Antibody Market
5.7 ESG Ratings of Leading Companies
6 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2020-2025)
6.3 Global CD30 (TNFRSF8) Antibody Market Size by Type (2020-2025)
6.4 Global CD30 (TNFRSF8) Antibody Price by Type (2020-2025)
7 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CD30 (TNFRSF8) Antibody Market Sales by Application (2020-2025)
7.3 Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Application (2020-2025)
7.4 Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2020-2025)
8 CD30 (TNFRSF8) ANTIBODY MARKET SALES BY REGION
8.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Region
8.2 Global CD30 (TNFRSF8) Antibody Market Size by Region
8.2.1 Global CD30 (TNFRSF8) Antibody Market Size by Region
8.2.2 Global CD30 (TNFRSF8) Antibody Market Size by Region
8.3 North America
8.3.1 North America CD30 (TNFRSF8) Antibody Sales by Country
8.3.2 North America CD30 (TNFRSF8) Antibody Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe CD30 (TNFRSF8) Antibody Sales by Country
8.4.2 Europe CD30 (TNFRSF8) Antibody Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region
8.5.2 Asia Pacific CD30 (TNFRSF8) Antibody Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America CD30 (TNFRSF8) Antibody Sales by Country
8.6.2 South America CD30 (TNFRSF8) Antibody Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region
8.7.2 Middle East and Africa CD30 (TNFRSF8) Antibody Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 CD30 (TNFRSF8) ANTIBODY MARKET PRODUCTION BY REGION
9.1 Global Production of CD30 (TNFRSF8) Antibody by Region(2020-2025)
9.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2020-2025)
9.3 Global CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America CD30 (TNFRSF8) Antibody Production
9.4.1 North America CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.4.2 North America CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe CD30 (TNFRSF8) Antibody Production
9.5.1 Europe CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.5.2 Europe CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan CD30 (TNFRSF8) Antibody Production (2020-2025)
9.6.1 Japan CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.6.2 Japan CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China CD30 (TNFRSF8) Antibody Production (2020-2025)
9.7.1 China CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.7.2 China CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Sino Biological, Inc.
10.1.1 Sino Biological, Inc. Basic Information
10.1.2 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.1.4 Sino Biological, Inc. Business Overview
10.1.5 Sino Biological, Inc. SWOT Analysis
10.1.6 Sino Biological, Inc. Recent Developments
10.2 Bio-Techne
10.2.1 Bio-Techne Basic Information
10.2.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
10.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Product Market Performance
10.2.4 Bio-Techne Business Overview
10.2.5 Bio-Techne SWOT Analysis
10.2.6 Bio-Techne Recent Developments
10.3 Thermo Fisher Scientific (China) Co., Ltd.
10.3.1 Thermo Fisher Scientific (China) Co., Ltd. Basic Information
10.3.2 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
10.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Market Performance
10.3.4 Thermo Fisher Scientific (China) Co., Ltd. Business Overview
10.3.5 Thermo Fisher Scientific (China) Co., Ltd. SWOT Analysis
10.3.6 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
10.4 Boster Biological Technology
10.4.1 Boster Biological Technology Basic Information
10.4.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
10.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Market Performance
10.4.4 Boster Biological Technology Business Overview
10.4.5 Boster Biological Technology Recent Developments
10.5 MyBiosource, Inc.
10.5.1 MyBiosource, Inc. Basic Information
10.5.2 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.5.4 MyBiosource, Inc. Business Overview
10.5.5 MyBiosource, Inc. Recent Developments
10.6 Abeomics Inc.
10.6.1 Abeomics Inc. Basic Information
10.6.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
10.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.6.4 Abeomics Inc. Business Overview
10.6.5 Abeomics Inc. Recent Developments
10.7 Abbexa
10.7.1 Abbexa Basic Information
10.7.2 Abbexa CD30 (TNFRSF8) Antibody Product Overview
10.7.3 Abbexa CD30 (TNFRSF8) Antibody Product Market Performance
10.7.4 Abbexa Business Overview
10.7.5 Abbexa Recent Developments
10.8 Cell Signaling Technology, Inc.
10.8.1 Cell Signaling Technology, Inc. Basic Information
10.8.2 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.8.4 Cell Signaling Technology, Inc. Business Overview
10.8.5 Cell Signaling Technology, Inc. Recent Developments
10.9 Creative Diagnostics
10.9.1 Creative Diagnostics Basic Information
10.9.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
10.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Market Performance
10.9.4 Creative Diagnostics Business Overview
10.9.5 Creative Diagnostics Recent Developments
10.10 OriGene Technologies, Inc.
10.10.1 OriGene Technologies, Inc. Basic Information
10.10.2 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.10.4 OriGene Technologies, Inc. Business Overview
10.10.5 OriGene Technologies, Inc. Recent Developments
10.11 Merck
10.11.1 Merck Basic Information
10.11.2 Merck CD30 (TNFRSF8) Antibody Product Overview
10.11.3 Merck CD30 (TNFRSF8) Antibody Product Market Performance
10.11.4 Merck Business Overview
10.11.5 Merck Recent Developments
10.12 Cayman Chemical
10.12.1 Cayman Chemical Basic Information
10.12.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
10.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product Market Performance
10.12.4 Cayman Chemical Business Overview
10.12.5 Cayman Chemical Recent Developments
10.13 CUSABIO
10.13.1 CUSABIO Basic Information
10.13.2 CUSABIO CD30 (TNFRSF8) Antibody Product Overview
10.13.3 CUSABIO CD30 (TNFRSF8) Antibody Product Market Performance
10.13.4 CUSABIO Business Overview
10.13.5 CUSABIO Recent Developments
10.14 Biotium
10.14.1 Biotium Basic Information
10.14.2 Biotium CD30 (TNFRSF8) Antibody Product Overview
10.14.3 Biotium CD30 (TNFRSF8) Antibody Product Market Performance
10.14.4 Biotium Business Overview
10.14.5 Biotium Recent Developments
10.15 BioLegend
10.15.1 BioLegend Basic Information
10.15.2 BioLegend CD30 (TNFRSF8) Antibody Product Overview
10.15.3 BioLegend CD30 (TNFRSF8) Antibody Product Market Performance
10.15.4 BioLegend Business Overview
10.15.5 BioLegend Recent Developments
10.16 Abcepta
10.16.1 Abcepta Basic Information
10.16.2 Abcepta CD30 (TNFRSF8) Antibody Product Overview
10.16.3 Abcepta CD30 (TNFRSF8) Antibody Product Market Performance
10.16.4 Abcepta Business Overview
10.16.5 Abcepta Recent Developments
10.17 ProSci Incorporated
10.17.1 ProSci Incorporated Basic Information
10.17.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
10.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Market Performance
10.17.4 ProSci Incorporated Business Overview
10.17.5 ProSci Incorporated Recent Developments
11 CD30 (TNFRSF8) ANTIBODY MARKET FORECAST BY REGION
11.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast
11.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.3 Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region
11.2.4 South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of CD30 (TNFRSF8) Antibody by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global CD30 (TNFRSF8) Antibody Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of CD30 (TNFRSF8) Antibody by Type (2026-2035)
12.1.2 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of CD30 (TNFRSF8) Antibody by Type (2026-2035)
12.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Application (2026-2035)
12.2.1 Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application
12.2.2 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of CD30 (TNFRSF8) Antibody
1.2 Key Market Segments
1.2.1 CD30 (TNFRSF8) Antibody Segment by Type
1.2.2 CD30 (TNFRSF8) Antibody Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CD30 (TNFRSF8) ANTIBODY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CD30 (TNFRSF8) ANTIBODY MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global CD30 (TNFRSF8) Antibody Product Life Cycle
3.3 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2020-2025)
3.4 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2020-2025)
3.5 CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global CD30 (TNFRSF8) Antibody Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 CD30 (TNFRSF8) Antibody Market Competitive Situation and Trends
3.8.1 CD30 (TNFRSF8) Antibody Market Concentration Rate
3.8.2 Global 5 and 10 Largest CD30 (TNFRSF8) Antibody Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 CD30 (TNFRSF8) ANTIBODY INDUSTRY CHAIN ANALYSIS
4.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CD30 (TNFRSF8) ANTIBODY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global CD30 (TNFRSF8) Antibody Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to CD30 (TNFRSF8) Antibody Market
5.7 ESG Ratings of Leading Companies
6 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2020-2025)
6.3 Global CD30 (TNFRSF8) Antibody Market Size by Type (2020-2025)
6.4 Global CD30 (TNFRSF8) Antibody Price by Type (2020-2025)
7 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CD30 (TNFRSF8) Antibody Market Sales by Application (2020-2025)
7.3 Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Application (2020-2025)
7.4 Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2020-2025)
8 CD30 (TNFRSF8) ANTIBODY MARKET SALES BY REGION
8.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Region
8.2 Global CD30 (TNFRSF8) Antibody Market Size by Region
8.2.1 Global CD30 (TNFRSF8) Antibody Market Size by Region
8.2.2 Global CD30 (TNFRSF8) Antibody Market Size by Region
8.3 North America
8.3.1 North America CD30 (TNFRSF8) Antibody Sales by Country
8.3.2 North America CD30 (TNFRSF8) Antibody Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe CD30 (TNFRSF8) Antibody Sales by Country
8.4.2 Europe CD30 (TNFRSF8) Antibody Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region
8.5.2 Asia Pacific CD30 (TNFRSF8) Antibody Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America CD30 (TNFRSF8) Antibody Sales by Country
8.6.2 South America CD30 (TNFRSF8) Antibody Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region
8.7.2 Middle East and Africa CD30 (TNFRSF8) Antibody Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 CD30 (TNFRSF8) ANTIBODY MARKET PRODUCTION BY REGION
9.1 Global Production of CD30 (TNFRSF8) Antibody by Region(2020-2025)
9.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2020-2025)
9.3 Global CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America CD30 (TNFRSF8) Antibody Production
9.4.1 North America CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.4.2 North America CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe CD30 (TNFRSF8) Antibody Production
9.5.1 Europe CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.5.2 Europe CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan CD30 (TNFRSF8) Antibody Production (2020-2025)
9.6.1 Japan CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.6.2 Japan CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China CD30 (TNFRSF8) Antibody Production (2020-2025)
9.7.1 China CD30 (TNFRSF8) Antibody Production Growth Rate (2020-2025)
9.7.2 China CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Sino Biological, Inc.
10.1.1 Sino Biological, Inc. Basic Information
10.1.2 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.1.4 Sino Biological, Inc. Business Overview
10.1.5 Sino Biological, Inc. SWOT Analysis
10.1.6 Sino Biological, Inc. Recent Developments
10.2 Bio-Techne
10.2.1 Bio-Techne Basic Information
10.2.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
10.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Product Market Performance
10.2.4 Bio-Techne Business Overview
10.2.5 Bio-Techne SWOT Analysis
10.2.6 Bio-Techne Recent Developments
10.3 Thermo Fisher Scientific (China) Co., Ltd.
10.3.1 Thermo Fisher Scientific (China) Co., Ltd. Basic Information
10.3.2 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
10.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Market Performance
10.3.4 Thermo Fisher Scientific (China) Co., Ltd. Business Overview
10.3.5 Thermo Fisher Scientific (China) Co., Ltd. SWOT Analysis
10.3.6 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
10.4 Boster Biological Technology
10.4.1 Boster Biological Technology Basic Information
10.4.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
10.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Market Performance
10.4.4 Boster Biological Technology Business Overview
10.4.5 Boster Biological Technology Recent Developments
10.5 MyBiosource, Inc.
10.5.1 MyBiosource, Inc. Basic Information
10.5.2 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.5.4 MyBiosource, Inc. Business Overview
10.5.5 MyBiosource, Inc. Recent Developments
10.6 Abeomics Inc.
10.6.1 Abeomics Inc. Basic Information
10.6.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
10.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.6.4 Abeomics Inc. Business Overview
10.6.5 Abeomics Inc. Recent Developments
10.7 Abbexa
10.7.1 Abbexa Basic Information
10.7.2 Abbexa CD30 (TNFRSF8) Antibody Product Overview
10.7.3 Abbexa CD30 (TNFRSF8) Antibody Product Market Performance
10.7.4 Abbexa Business Overview
10.7.5 Abbexa Recent Developments
10.8 Cell Signaling Technology, Inc.
10.8.1 Cell Signaling Technology, Inc. Basic Information
10.8.2 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.8.4 Cell Signaling Technology, Inc. Business Overview
10.8.5 Cell Signaling Technology, Inc. Recent Developments
10.9 Creative Diagnostics
10.9.1 Creative Diagnostics Basic Information
10.9.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
10.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Market Performance
10.9.4 Creative Diagnostics Business Overview
10.9.5 Creative Diagnostics Recent Developments
10.10 OriGene Technologies, Inc.
10.10.1 OriGene Technologies, Inc. Basic Information
10.10.2 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
10.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.10.4 OriGene Technologies, Inc. Business Overview
10.10.5 OriGene Technologies, Inc. Recent Developments
10.11 Merck
10.11.1 Merck Basic Information
10.11.2 Merck CD30 (TNFRSF8) Antibody Product Overview
10.11.3 Merck CD30 (TNFRSF8) Antibody Product Market Performance
10.11.4 Merck Business Overview
10.11.5 Merck Recent Developments
10.12 Cayman Chemical
10.12.1 Cayman Chemical Basic Information
10.12.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
10.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product Market Performance
10.12.4 Cayman Chemical Business Overview
10.12.5 Cayman Chemical Recent Developments
10.13 CUSABIO
10.13.1 CUSABIO Basic Information
10.13.2 CUSABIO CD30 (TNFRSF8) Antibody Product Overview
10.13.3 CUSABIO CD30 (TNFRSF8) Antibody Product Market Performance
10.13.4 CUSABIO Business Overview
10.13.5 CUSABIO Recent Developments
10.14 Biotium
10.14.1 Biotium Basic Information
10.14.2 Biotium CD30 (TNFRSF8) Antibody Product Overview
10.14.3 Biotium CD30 (TNFRSF8) Antibody Product Market Performance
10.14.4 Biotium Business Overview
10.14.5 Biotium Recent Developments
10.15 BioLegend
10.15.1 BioLegend Basic Information
10.15.2 BioLegend CD30 (TNFRSF8) Antibody Product Overview
10.15.3 BioLegend CD30 (TNFRSF8) Antibody Product Market Performance
10.15.4 BioLegend Business Overview
10.15.5 BioLegend Recent Developments
10.16 Abcepta
10.16.1 Abcepta Basic Information
10.16.2 Abcepta CD30 (TNFRSF8) Antibody Product Overview
10.16.3 Abcepta CD30 (TNFRSF8) Antibody Product Market Performance
10.16.4 Abcepta Business Overview
10.16.5 Abcepta Recent Developments
10.17 ProSci Incorporated
10.17.1 ProSci Incorporated Basic Information
10.17.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
10.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Market Performance
10.17.4 ProSci Incorporated Business Overview
10.17.5 ProSci Incorporated Recent Developments
11 CD30 (TNFRSF8) ANTIBODY MARKET FORECAST BY REGION
11.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast
11.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.3 Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region
11.2.4 South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of CD30 (TNFRSF8) Antibody by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global CD30 (TNFRSF8) Antibody Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of CD30 (TNFRSF8) Antibody by Type (2026-2035)
12.1.2 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of CD30 (TNFRSF8) Antibody by Type (2026-2035)
12.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Application (2026-2035)
12.2.1 Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application
12.2.2 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 4. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 5. CD30 (TNFRSF8) Antibody Market Size Comparison by Region (M USD)
Table 6. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2020-2025)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD30 (TNFRSF8) Antibody as of 2025)
Table 11. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global CD30 (TNFRSF8) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CD30 (TNFRSF8) Antibody Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global CD30 (TNFRSF8) Antibody Sales by Type (K MT)
Table 27. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 28. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Type (2020-2025)
Table 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2020-2025)
Table 30. Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Type (2020-2025)
Table 31. Global CD30 (TNFRSF8) Antibody Market Share by Type (2020-2025)
Table 32. Global CD30 (TNFRSF8) Antibody Price (USD/KG) by Type (2020-2025)
Table 33. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Application
Table 34. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 35. Global CD30 (TNFRSF8) Antibody Sales by Application (2020-2025) & (K MT)
Table 36. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2020-2025)
Table 37. Global CD30 (TNFRSF8) Antibody Market Size by Application (2020-2025) & (M USD)
Table 38. Global CD30 (TNFRSF8) Antibody Market Share by Application (2020-2025)
Table 39. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2020-2025)
Table 40. Global CD30 (TNFRSF8) Antibody Sales by Region (2020-2025) & (K MT)
Table 41. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2020-2025)
Table 42. Global CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025) & (M USD)
Table 43. Global CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025)
Table 44. North America CD30 (TNFRSF8) Antibody Sales by Country (2020-2025) & (K MT)
Table 45. North America CD30 (TNFRSF8) Antibody Market Size by Country (2020-2025) & (M USD)
Table 46. Europe CD30 (TNFRSF8) Antibody Sales by Country (2020-2025) & (K MT)
Table 47. Europe CD30 (TNFRSF8) Antibody Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025) & (M USD)
Table 50. South America CD30 (TNFRSF8) Antibody Sales by Country (2020-2025) & (K MT)
Table 51. South America CD30 (TNFRSF8) Antibody Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025) & (M USD)
Table 54. Global CD30 (TNFRSF8) Antibody Production (K MT) by Region(2020-2025)
Table 55. Global CD30 (TNFRSF8) Antibody Revenue (US$ Million) by Region (2020-2025)
Table 56. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2020-2025)
Table 57. Global CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sino Biological, Inc. Basic Information
Table 63. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 64. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sino Biological, Inc. Business Overview
Table 66. Sino Biological, Inc. SWOT Analysis
Table 67. Sino Biological, Inc. Recent Developments
Table 68. Bio-Techne Basic Information
Table 69. Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
Table 70. Bio-Techne CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Bio-Techne Business Overview
Table 72. Bio-Techne SWOT Analysis
Table 73. Bio-Techne Recent Developments
Table 74. Thermo Fisher Scientific (China) Co., Ltd. Basic Information
Table 75. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
Table 76. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Thermo Fisher Scientific (China) Co., Ltd. Business Overview
Table 78. Thermo Fisher Scientific (China) Co., Ltd. SWOT Analysis
Table 79. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
Table 80. Boster Biological Technology Basic Information
Table 81. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
Table 82. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Boster Biological Technology Business Overview
Table 84. Boster Biological Technology Recent Developments
Table 85. MyBiosource, Inc. Basic Information
Table 86. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 87. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. MyBiosource, Inc. Business Overview
Table 89. MyBiosource, Inc. Recent Developments
Table 90. Abeomics Inc. Basic Information
Table 91. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 92. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Abeomics Inc. Business Overview
Table 94. Abeomics Inc. Recent Developments
Table 95. Abbexa Basic Information
Table 96. Abbexa CD30 (TNFRSF8) Antibody Product Overview
Table 97. Abbexa CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Abbexa Business Overview
Table 99. Abbexa Recent Developments
Table 100. Cell Signaling Technology, Inc. Basic Information
Table 101. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 102. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Cell Signaling Technology, Inc. Business Overview
Table 104. Cell Signaling Technology, Inc. Recent Developments
Table 105. Creative Diagnostics Basic Information
Table 106. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
Table 107. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Creative Diagnostics Business Overview
Table 109. Creative Diagnostics Recent Developments
Table 110. OriGene Technologies, Inc. Basic Information
Table 111. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 112. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. OriGene Technologies, Inc. Business Overview
Table 114. OriGene Technologies, Inc. Recent Developments
Table 115. Merck Basic Information
Table 116. Merck CD30 (TNFRSF8) Antibody Product Overview
Table 117. Merck CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Merck Business Overview
Table 119. Merck Recent Developments
Table 120. Cayman Chemical Basic Information
Table 121. Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
Table 122. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Cayman Chemical Business Overview
Table 124. Cayman Chemical Recent Developments
Table 125. CUSABIO Basic Information
Table 126. CUSABIO CD30 (TNFRSF8) Antibody Product Overview
Table 127. CUSABIO CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. CUSABIO Business Overview
Table 129. CUSABIO Recent Developments
Table 130. Biotium Basic Information
Table 131. Biotium CD30 (TNFRSF8) Antibody Product Overview
Table 132. Biotium CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Biotium Business Overview
Table 134. Biotium Recent Developments
Table 135. BioLegend Basic Information
Table 136. BioLegend CD30 (TNFRSF8) Antibody Product Overview
Table 137. BioLegend CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. BioLegend Business Overview
Table 139. BioLegend Recent Developments
Table 140. Abcepta Basic Information
Table 141. Abcepta CD30 (TNFRSF8) Antibody Product Overview
Table 142. Abcepta CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Abcepta Business Overview
Table 144. Abcepta Recent Developments
Table 145. ProSci Incorporated Basic Information
Table 146. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
Table 147. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. ProSci Incorporated Business Overview
Table 149. ProSci Incorporated Recent Developments
Table 150. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2026-2035) & (K MT)
Table 151. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2026-2035) & (M USD)
Table 152. North America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (K MT)
Table 153. North America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (K MT)
Table 155. Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 156. Asia Pacific CD30 (TNFRSF8) Antibody Sales Forecast by Region (2026-2035) & (K MT)
Table 157. Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2026-2035) & (M USD)
Table 158. South America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (K MT)
Table 159. South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 160. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (Units)
Table 161. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 162. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2026-2035) & (K MT)
Table 163. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2026-2035) & (M USD)
Table 164. Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2026-2035) & (USD/KG)
Table 165. Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application (2026-2035)
Table 166. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 4. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 5. CD30 (TNFRSF8) Antibody Market Size Comparison by Region (M USD)
Table 6. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2020-2025)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD30 (TNFRSF8) Antibody as of 2025)
Table 11. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global CD30 (TNFRSF8) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CD30 (TNFRSF8) Antibody Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global CD30 (TNFRSF8) Antibody Sales by Type (K MT)
Table 27. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 28. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Type (2020-2025)
Table 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2020-2025)
Table 30. Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Type (2020-2025)
Table 31. Global CD30 (TNFRSF8) Antibody Market Share by Type (2020-2025)
Table 32. Global CD30 (TNFRSF8) Antibody Price (USD/KG) by Type (2020-2025)
Table 33. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Application
Table 34. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 35. Global CD30 (TNFRSF8) Antibody Sales by Application (2020-2025) & (K MT)
Table 36. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2020-2025)
Table 37. Global CD30 (TNFRSF8) Antibody Market Size by Application (2020-2025) & (M USD)
Table 38. Global CD30 (TNFRSF8) Antibody Market Share by Application (2020-2025)
Table 39. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2020-2025)
Table 40. Global CD30 (TNFRSF8) Antibody Sales by Region (2020-2025) & (K MT)
Table 41. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2020-2025)
Table 42. Global CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025) & (M USD)
Table 43. Global CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025)
Table 44. North America CD30 (TNFRSF8) Antibody Sales by Country (2020-2025) & (K MT)
Table 45. North America CD30 (TNFRSF8) Antibody Market Size by Country (2020-2025) & (M USD)
Table 46. Europe CD30 (TNFRSF8) Antibody Sales by Country (2020-2025) & (K MT)
Table 47. Europe CD30 (TNFRSF8) Antibody Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025) & (M USD)
Table 50. South America CD30 (TNFRSF8) Antibody Sales by Country (2020-2025) & (K MT)
Table 51. South America CD30 (TNFRSF8) Antibody Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025) & (M USD)
Table 54. Global CD30 (TNFRSF8) Antibody Production (K MT) by Region(2020-2025)
Table 55. Global CD30 (TNFRSF8) Antibody Revenue (US$ Million) by Region (2020-2025)
Table 56. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2020-2025)
Table 57. Global CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sino Biological, Inc. Basic Information
Table 63. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 64. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sino Biological, Inc. Business Overview
Table 66. Sino Biological, Inc. SWOT Analysis
Table 67. Sino Biological, Inc. Recent Developments
Table 68. Bio-Techne Basic Information
Table 69. Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
Table 70. Bio-Techne CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Bio-Techne Business Overview
Table 72. Bio-Techne SWOT Analysis
Table 73. Bio-Techne Recent Developments
Table 74. Thermo Fisher Scientific (China) Co., Ltd. Basic Information
Table 75. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
Table 76. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Thermo Fisher Scientific (China) Co., Ltd. Business Overview
Table 78. Thermo Fisher Scientific (China) Co., Ltd. SWOT Analysis
Table 79. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
Table 80. Boster Biological Technology Basic Information
Table 81. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
Table 82. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Boster Biological Technology Business Overview
Table 84. Boster Biological Technology Recent Developments
Table 85. MyBiosource, Inc. Basic Information
Table 86. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 87. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. MyBiosource, Inc. Business Overview
Table 89. MyBiosource, Inc. Recent Developments
Table 90. Abeomics Inc. Basic Information
Table 91. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 92. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Abeomics Inc. Business Overview
Table 94. Abeomics Inc. Recent Developments
Table 95. Abbexa Basic Information
Table 96. Abbexa CD30 (TNFRSF8) Antibody Product Overview
Table 97. Abbexa CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Abbexa Business Overview
Table 99. Abbexa Recent Developments
Table 100. Cell Signaling Technology, Inc. Basic Information
Table 101. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 102. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Cell Signaling Technology, Inc. Business Overview
Table 104. Cell Signaling Technology, Inc. Recent Developments
Table 105. Creative Diagnostics Basic Information
Table 106. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
Table 107. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Creative Diagnostics Business Overview
Table 109. Creative Diagnostics Recent Developments
Table 110. OriGene Technologies, Inc. Basic Information
Table 111. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 112. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. OriGene Technologies, Inc. Business Overview
Table 114. OriGene Technologies, Inc. Recent Developments
Table 115. Merck Basic Information
Table 116. Merck CD30 (TNFRSF8) Antibody Product Overview
Table 117. Merck CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Merck Business Overview
Table 119. Merck Recent Developments
Table 120. Cayman Chemical Basic Information
Table 121. Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
Table 122. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Cayman Chemical Business Overview
Table 124. Cayman Chemical Recent Developments
Table 125. CUSABIO Basic Information
Table 126. CUSABIO CD30 (TNFRSF8) Antibody Product Overview
Table 127. CUSABIO CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. CUSABIO Business Overview
Table 129. CUSABIO Recent Developments
Table 130. Biotium Basic Information
Table 131. Biotium CD30 (TNFRSF8) Antibody Product Overview
Table 132. Biotium CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Biotium Business Overview
Table 134. Biotium Recent Developments
Table 135. BioLegend Basic Information
Table 136. BioLegend CD30 (TNFRSF8) Antibody Product Overview
Table 137. BioLegend CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. BioLegend Business Overview
Table 139. BioLegend Recent Developments
Table 140. Abcepta Basic Information
Table 141. Abcepta CD30 (TNFRSF8) Antibody Product Overview
Table 142. Abcepta CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Abcepta Business Overview
Table 144. Abcepta Recent Developments
Table 145. ProSci Incorporated Basic Information
Table 146. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
Table 147. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. ProSci Incorporated Business Overview
Table 149. ProSci Incorporated Recent Developments
Table 150. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2026-2035) & (K MT)
Table 151. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2026-2035) & (M USD)
Table 152. North America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (K MT)
Table 153. North America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (K MT)
Table 155. Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 156. Asia Pacific CD30 (TNFRSF8) Antibody Sales Forecast by Region (2026-2035) & (K MT)
Table 157. Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2026-2035) & (M USD)
Table 158. South America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (K MT)
Table 159. South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 160. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Forecast by Country (2026-2035) & (Units)
Table 161. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2026-2035) & (M USD)
Table 162. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2026-2035) & (K MT)
Table 163. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2026-2035) & (M USD)
Table 164. Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2026-2035) & (USD/KG)
Table 165. Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application (2026-2035)
Table 166. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of CD30 (TNFRSF8) Antibody
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CD30 (TNFRSF8) Antibody Market Size (M USD), 2025-2035
Figure 5. Global CD30 (TNFRSF8) Antibody Market Size (M USD) (2020-2035)
Figure 6. Global CD30 (TNFRSF8) Antibody Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CD30 (TNFRSF8) Antibody Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global CD30 (TNFRSF8) Antibody Product Life Cycle
Figure 13. CD30 (TNFRSF8) Antibody Sales Share by Manufacturers in 2025
Figure 14. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers in 2025
Figure 15. CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by CD30 (TNFRSF8) Antibody Revenue in 2025
Figure 18. Industry Chain Map of CD30 (TNFRSF8) Antibody
Figure 19. Global CD30 (TNFRSF8) Antibody Market PEST Analysis
Figure 20. Global CD30 (TNFRSF8) Antibody Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global CD30 (TNFRSF8) Antibody Market Share by Type
Figure 27. Sales Market Share of CD30 (TNFRSF8) Antibody by Type (2020-2025)
Figure 28. Sales Market Share of CD30 (TNFRSF8) Antibody by Type in 2025
Figure 29. Market Share of CD30 (TNFRSF8) Antibody by Type (2020-2025)
Figure 30. Market Share of CD30 (TNFRSF8) Antibody by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global CD30 (TNFRSF8) Antibody Market Share by Application
Figure 33. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2020-2025)
Figure 34. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application in 2025
Figure 35. Global CD30 (TNFRSF8) Antibody Market Share by Application (2020-2025)
Figure 36. Global CD30 (TNFRSF8) Antibody Market Share by Application in 2025
Figure 37. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2020-2025)
Figure 38. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2020-2025)
Figure 39. Global CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025)
Figure 40. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2024
Figure 43. North America CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America CD30 (TNFRSF8) Antibody Market Size by Country in 2024
Figure 45. U.S. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada CD30 (TNFRSF8) Antibody Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada CD30 (TNFRSF8) Antibody Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico CD30 (TNFRSF8) Antibody Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico CD30 (TNFRSF8) Antibody Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2024
Figure 53. Europe CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe CD30 (TNFRSF8) Antibody Market Size by Country in 2024
Figure 55. Germany CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 66. Asia Pacific CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2024
Figure 67. Asia Pacific CD30 (TNFRSF8) Antibody Market Size by Region in 2024
Figure 68. China CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 79. South America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2024
Figure 80. South America CD30 (TNFRSF8) Antibody Market Size and Growth Rate (M USD)
Figure 81. South America CD30 (TNFRSF8) Antibody Market Size by Country in 2024
Figure 82. Brazil CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2024
Figure 90. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size by Region in 2024
Figure 92. Saudi Arabia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global CD30 (TNFRSF8) Antibody Production Market Share by Region (2020-2025)
Figure 103. North America CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 106. China CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 107. Global CD30 (TNFRSF8) Antibody Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Type (2026-2035)
Figure 111. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2026-2035)
Figure 112. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of CD30 (TNFRSF8) Antibody
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CD30 (TNFRSF8) Antibody Market Size (M USD), 2025-2035
Figure 5. Global CD30 (TNFRSF8) Antibody Market Size (M USD) (2020-2035)
Figure 6. Global CD30 (TNFRSF8) Antibody Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CD30 (TNFRSF8) Antibody Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global CD30 (TNFRSF8) Antibody Product Life Cycle
Figure 13. CD30 (TNFRSF8) Antibody Sales Share by Manufacturers in 2025
Figure 14. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers in 2025
Figure 15. CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by CD30 (TNFRSF8) Antibody Revenue in 2025
Figure 18. Industry Chain Map of CD30 (TNFRSF8) Antibody
Figure 19. Global CD30 (TNFRSF8) Antibody Market PEST Analysis
Figure 20. Global CD30 (TNFRSF8) Antibody Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global CD30 (TNFRSF8) Antibody Market Share by Type
Figure 27. Sales Market Share of CD30 (TNFRSF8) Antibody by Type (2020-2025)
Figure 28. Sales Market Share of CD30 (TNFRSF8) Antibody by Type in 2025
Figure 29. Market Share of CD30 (TNFRSF8) Antibody by Type (2020-2025)
Figure 30. Market Share of CD30 (TNFRSF8) Antibody by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global CD30 (TNFRSF8) Antibody Market Share by Application
Figure 33. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2020-2025)
Figure 34. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application in 2025
Figure 35. Global CD30 (TNFRSF8) Antibody Market Share by Application (2020-2025)
Figure 36. Global CD30 (TNFRSF8) Antibody Market Share by Application in 2025
Figure 37. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2020-2025)
Figure 38. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2020-2025)
Figure 39. Global CD30 (TNFRSF8) Antibody Market Size by Region (2020-2025)
Figure 40. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2024
Figure 43. North America CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America CD30 (TNFRSF8) Antibody Market Size by Country in 2024
Figure 45. U.S. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada CD30 (TNFRSF8) Antibody Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada CD30 (TNFRSF8) Antibody Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico CD30 (TNFRSF8) Antibody Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico CD30 (TNFRSF8) Antibody Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2024
Figure 53. Europe CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe CD30 (TNFRSF8) Antibody Market Size by Country in 2024
Figure 55. Germany CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 66. Asia Pacific CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2024
Figure 67. Asia Pacific CD30 (TNFRSF8) Antibody Market Size by Region in 2024
Figure 68. China CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 79. South America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2024
Figure 80. South America CD30 (TNFRSF8) Antibody Market Size and Growth Rate (M USD)
Figure 81. South America CD30 (TNFRSF8) Antibody Market Size by Country in 2024
Figure 82. Brazil CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2024
Figure 90. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size by Region in 2024
Figure 92. Saudi Arabia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa CD30 (TNFRSF8) Antibody Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global CD30 (TNFRSF8) Antibody Production Market Share by Region (2020-2025)
Figure 103. North America CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 106. China CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2020-2025)
Figure 107. Global CD30 (TNFRSF8) Antibody Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Type (2026-2035)
Figure 111. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2026-2035)
Figure 112. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Application (2026-2035)
